The abstract is read at the publisher; the summary is JClub's.
lncSigAML, a bone marrow-derived 10-lncRNA signature, stratifies pediatric acute myeloid leukemia patients into high- and low-risk groups with cross-validated HR = 2.87 (P < 0.001).
- Why it matters: AML risk stratification based on cytogenetics and genetics leaves prognostic heterogeneity, especially within intermediate-risk disease, insufficiently captured.
- What they did: The signature was built from TARGET-AML pediatric bone marrow samples (n = 1,594) and validated across four datasets from TARGET-AML, Beat AML, and TCGA-LAML (n = 1,087) using random survival forest.
- The result: Across cross-cohort and cross-tissue datasets, pooled HR = 2.91 (95%CI: 2.31-3.68; P < 0.001) and low-risk meta-analysis showed higher 1-, 3-, and 5-year overall survival (80.5%, 63.4%, 55.3% vs. 52.1%, 28.1%, 23.9%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.